Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.-Reference-Cited by-同舟云学术

Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.

Published:2016-05-20 Issue:15_suppl Volume:34 Page:6003-6003
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bourhis Jean¹,Sun xu Shan²,Sire Christian³,Tao Yungan⁴,Martin Laurent⁵,Khoury Cedric⁶,Maingon Philippe⁷,Bardet Etienne⁸,Lapeyre Michel⁹,Chatellier Thierry¹⁰,Ollivier Nathalie¹¹,Cornely Alexandre¹¹,Auperin Anne¹¹

Affiliation:

1. Lausanne University Medical Center, Lausanne, Switzerland;

2. Besançon Hospital, Besancon, France;

3. CH de Bretagne Sud, Lorient, France;

4. Institut Gustave Roussy, Villejuif, France;

5. Centre Guillaume Le Conquerant, Le Havre, France;

6. Centre Georges-François Leclerc, Dijon, France;

7. Georges-François Leclerc Center, Radiotherapy Department, Dijon, France;

8. Centre Rene Gauducheau, Nantes, France;

9. Centre Jean Perrin, Clermont, France;

10. Clinique Mutualiste, Saint Nazaire, France;

11. Institute Gustave Roussy, Villejuif, France;